Literature DB >> 27040806

Post-mortem findings in a patient with avian influenza A (H5N6) virus infection.

R Gao1, M Pan2, X Li1, X Zou1, X Zhao1, T Li2, H Yang2, S Zou1, H Bo1, J Xu2, S Li2, M Zhang3, Z Li4, D Wang1, S R Zaki5, Y Shu6.   

Abstract

Avian influenza A (H5N6) has been found to infect humans, and has resulted in ten cases with six deaths in China since 2014. Here, we describe the systematic post-mortem pathology of a patient fatally infected with H5N6 virus and evaluate the associated pathogenesis compared with H1N1 pdm09 fatal cases. The most prominent histopathological features were diffuse alveolar damage and pulmonary vasculitis in the lungs of the patient. The virus disseminated to extrapulmonary organs, including the brain. Compared with H1N1 pdm09 fatal infection, H5N6 infection induced a more exacerbated immune response involving overt pulmonary inflammation, which led to alveolar damage and respiratory failure.
Copyright © 2016 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  H5N6; highly pathogenic avian influenza virus; histology; immunopathological lesion; severe pneumonia

Mesh：

Substances：

Year:  2016        PMID： 27040806     DOI： 10.1016/j.cmi.2016.03.017

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN： 1198-743X            Impact factor:   8.067


  6 in total

1.  Efficacy of Neuraminidase Inhibitors against H5N6 Highly Pathogenic Avian Influenza Virus in a Nonhuman Primate Model.

Authors:  Cong Thanh Nguyen; Saori Suzuki; Yasushi Itoh; Hirohito Ishigaki; Misako Nakayama; Kaori Hayashi; Keita Matsuno; Masatoshi Okamatsu; Yoshihiro Sakoda; Hiroshi Kida; Kazumasa Ogasawara
Journal:  Antimicrob Agents Chemother       Date:  2020-06-23       Impact factor: 5.191

2.  Seasonal Influenza Split Vaccines Confer Partial Cross-Protection against Heterologous Influenza Virus in Ferrets When Combined with the CAF01 Adjuvant.

Authors:  Dennis Christensen; Jan P Christensen; Karen S Korsholm; Louise K Isling; Karin Erneholm; Allan R Thomsen; Peter Andersen
Journal:  Front Immunol       Date:  2018-01-08       Impact factor: 7.561

3.  C-Reactive Protein Mediating Immunopathological Lesions: A Potential Treatment Option for Severe Influenza A Diseases.

Authors:  Rongbao Gao; Lijie Wang; Tian Bai; Ye Zhang; Hong Bo; Yuelong Shu
Journal:  EBioMedicine       Date:  2017-07-13       Impact factor: 8.143

4.  Successful combinatorial therapy of sirolimus and neuraminidase inhibitors in a patient with highly pathogenic avian influenza A (H5N6) virus: a case report.

Authors:  Qiaojun Zeng; Jiwen Wang; Xiang Zhang; Liang Chen; Lin Zhou; Fang Kuang; Linjie Huang; Fengqin Xu; Xun Zhu; Jun Shen; Shanping Jiang
Journal:  Ann Transl Med       Date:  2022-03

Review 5.  Pandemic potential of highly pathogenic avian influenza clade 2.3.4.4 A(H5) viruses.

Authors:  Reina Yamaji; Magdi D Saad; Charles T Davis; David E Swayne; Dayan Wang; Frank Y K Wong; John W McCauley; J S Malik Peiris; Richard J Webby; Ron A M Fouchier; Yoshihiro Kawaoka; Wenqing Zhang
Journal:  Rev Med Virol       Date:  2020-03-05       Impact factor: 11.043

6.  Characterization of highly pathogenic avian influenza H5Nx viruses in the ferret model.

Authors:  Joanna A Pulit-Penaloza; Nicole Brock; Claudia Pappas; Xiangjie Sun; Jessica A Belser; Hui Zeng; Terrence M Tumpey; Taronna R Maines
Journal:  Sci Rep       Date:  2020-07-29       Impact factor: 4.996
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.